Skip to main content

Advertisement

Advertisement

Record S$700,000 worth of illegal sexual enhancement drugs seized in Geylang

SINGAPORE – More than 300,000 units of assorted sexual enhancement drugs (SED), worth a street value of S$700,000, were seized from a private apartment in Geylang on last week.

Clockwise: Illegal sexual enhancement drugs were seized from the suspect's cupboards, under the bed and in boxes and bags. Photo: Health Sciences Authority

Clockwise: Illegal sexual enhancement drugs were seized from the suspect's cupboards, under the bed and in boxes and bags. Photo: Health Sciences Authority

Join our WhatsApp or Telegram channels for the latest updates, or follow us on TikTok and Instagram.

Quiz of the week

How well do you know the news? Test your knowledge.

SINGAPORE – More than 300,000 units of assorted sexual enhancement drugs (SED), worth a street value of S$700,000, were seized from a private apartment in Geylang on last week.

This makes it the largest seizure of illegal SEDs by the Health Sciences Authority (HSA) and the Singapore Police Force in five years, said the HSA on Wednesday (Sept 27). 

The largest seizure to date hauled in 389,268 units of illegal SEDS in 2012, which were estimated to be worth S$1 million.

Last Friday, the HSA apprehended a 26-year-old male Chinese national outside a private residential apartment in Lorong 32 Geylang, after receiving an alert from the Immigration & Checkpoints Authority (ICA) that he was the intended recipient of a parcel believed to contain a large assortment of illegal health products.

The suspect led the authorities back to his rented room in the building, where more illegal SEDs – such as Africa Black Ant, Maxman and Black Ant King – were recovered. Another man was also found in the room.

Both men are currently assisting in investigations.

If found guilty, the suspects are liable to be imprisoned for up to three years and/or a fine of up to S$100,000.
 

Read more of the latest in

Advertisement

Advertisement

Stay in the know. Anytime. Anywhere.

Subscribe to our newsletter for the top features, insights and must reads delivered straight to your inbox.

By clicking subscribe, I agree for my personal data to be used to send me TODAY newsletters, promotional offers and for research and analysis.